Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report-Reference-Cited by-同舟云学术

Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report

Published:2018-04-11 Issue:4 Volume:33 Page:546-550
ISSN:0733-2459
Container-title:Journal of Clinical Apheresis
language:en
Short-container-title:J Clin Apher

Author:

Zenti M. G.¹^ORCID,Stefanutti C.²,Sanga V.¹,Altomari A.¹,Fabris A.³,Dauriz M.¹^ORCID,Bonora E.¹

Affiliation:

1. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine; University Hospital of Verona; Verona Italy

2. Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Immunohematology and Transfusion Medicine, Department of Molecular Medicine; ‘‘Sapienza’’ University of Rome, ‘‘Umberto I’’ Hospital; Rome Italy

3. Section of Nephrology, Department of Medicine; University Hospital of Verona; Verona Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jca.21632/fullpdf

Reference16 articles.

1. Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia;Goldstein;N Engl J Med.,1983

2. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society;Nordestgaard;Eur Heart J.,2013

3. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment;Wiegman;Eur Heart J.,2015

4. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR);Piepoli;Atherosclerosis.,2016

5. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management;Stroes;Eur Heart J.,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 Biology and Its Role in Atherothrombosis;International Journal of Molecular Sciences;2021-05-30

2. Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents;Current Atherosclerosis Reports;2021-05-08

3. Von der Diät bis zu Lipoproteinapherese;Dialyse aktuell;2020-11

4. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study;Journal of Cardiovascular Pharmacology and Therapeutics;2020-07-30

5. Lipoprotein Apheresis and PCSK9-Inhibitors. Impact on Atherogenic Lipoproteins and Anti-Inflammatory Mediators in Familial Hypercholesterolaemia;Current Pharmaceutical Design;2019-01-02